The Study
Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trial.
This study is like a fair test where half the people got a new medicine and half got a sugar pill, and both groups were losing weight with the same drug. The group with the new medicine kept more muscle. That means the medicine probably helped, but we don’t know if it would work for everyone.
Analysis score
Maximum 90 for a randomized controlled trial.
Where the score came from
When people take tirzepatide to lose weight, they often lose muscle too. This study tested a new drug called apitegromab to see if it could stop that muscle loss.
Where does this study sit?
Systematic Reviews & Meta-analyses
Max 100Randomized Trials
Max 90Cohort Studies
Max 72Case-Control
Max 58Cross-Sectional
Max 44Case Reports & Series
Max 30Expert Opinion
Max 569 / 100
Quality score
Participants are randomly assigned to treatment or control groups, minimizing bias. Considered the gold standard for testing whether an intervention causes an effect.
Key takeaways
Summary
Based on the study abstract and findings.
- 1Yes — preserving muscle helps maintain metabolism, strength, and long-term health during weight loss, making this a meaningful improvement.
- 2People who got apitegromab lost 1.9 kg less muscle than those who got a placebo, even though both groups lost the same total weight.
- 3Muscle made up only 14.6% of weight loss with apitegromab vs.
- 430.2% without.
- 5The muscle-saving effect lasted 8 weeks after stopping the drug.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
Nature medicine
Year
2026
Authors
R. Pratley, D. Denham, R. Trivedi, E. Watkins, L. Connery, J. Barnes, Dongzi Yu, J. Hong, C. Simard, K. Umans, Lan Liu, G. S. Tirucherai, J. Marantz
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.